CoChat

Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect

Open access
van de Kamp, Jiddeke M., Pouwels, Petra J. W., Aarsen, Femke K., ten Hoopen, Leontine W., Knol, Dirk L., de Klerk, Johannes B., de Coo, Ireneus F., Huijmans, Jan G. M., Jakobs, Cornelis, van der Knaap, Marjo S., Salomons, Gajja S., Mancini, Grazia M. S. · 2012 · Journal of Inherited Metabolic Disease

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

Abstract

The creatine transporter (CRTR) defect is a recently discovered cause of X-linked intellectual disability for which treatment options have been explored. Creatine monotherapy has not proved effective, and the effect of treatment with L-arginine is still controversial. Nine boys between 8 months and 10 years old with molecularly confirmed CRTR defect were followed with repeated (1)H-MRS and neuropsychological assessments during 4-6 years of combination treatment with creatine monohydrate, L-arginine, and glycine. Treatment did not lead to a significant increase in cerebral creatine content as observed with H(1)-MRS. After an initial improvement in locomotor and personal-social IQ subscales, no lasting clinical improvement was recorded. Additionally, we noticed an age-related decline in IQ subscales in boys affected with the CRTR defect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10545-011-9345-1

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Treatment protocol and timing of neuropsychological assessments and 1H-MRS in the individual patients. Double-hatched bars depict treatment with creatine and L-arginine. Hatched bars depict treatment with creatine, L-arginine, and glycine. Black rectangles depict neuropsychological assessments and gray rectangles 1H-MRS assessments
Fig. 1 Treatment protocol and timing of neuropsychological assessments and 1H-MRS in the individual patients. Double-hatched bars depict treatment with creatine and L-arginine. Hatched bars depict treatment with creatine, L-arginine, and glycine. Black rectangles depict neuropsychological assessments and gray rectangles 1H-MRS assessmentsCC BY-NC · PubMed Central
Fig. 2 Griffiths developmental scores (locomotor, personal-social, hearing and speech, and hand and eye coordination subscales) of the nine patients plotted against age. The dots depict the measurements, the lines connect the measurements of one patient, and the numbers stand for the treatment conditions (0 before start, 1 during treatment with creatine and arginine, 2 during treatment with creatine, arginine, and glycine)
Fig. 2 Griffiths developmental scores (locomotor, personal-social, hearing and speech, and hand and eye coordination subscales) of the nine patients plotted against age. The dots depict the measurements, the lines connect the measurements of one patient, and the numbers stand for the treatment conditions (0 before start, 1 during treatment with creatine and arginine, 2 during treatment with creatine, arginine, and glycine)CC BY-NC · PubMed Central
Fig. 3 Gray matter 1H-MRS spectra of patient 4 at start of treatment at age 5 years 11 months and during treatment at age 8 years 8 months. Cr concentrations in this brain region are 1.5 and 1.7 mM, respectively
Fig. 3 Gray matter 1H-MRS spectra of patient 4 at start of treatment at age 5 years 11 months and during treatment at age 8 years 8 months. Cr concentrations in this brain region are 1.5 and 1.7 mM, respectivelyCC BY-NC · PubMed Central
Fig. 4 Total creatine concentrations in gray matter, white matter, basal ganglia and cerebellum of the nine patients plotted against age. The dots depict the individual values, the lines connect the measurements of one patient. The first measurements are before the start of treatment
Fig. 4 Total creatine concentrations in gray matter, white matter, basal ganglia and cerebellum of the nine patients plotted against age. The dots depict the individual values, the lines connect the measurements of one patient. The first measurements are before the start of treatmentCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Mercimek‐Mahmutoglu S, 2009, GeneReviews at GeneTests: medical genetics information resource (database online)

Cited by

See all 62

Metadata

Authors
van de Kamp, J. M., Pouwels, P. J. W., Aarsen, F. K., ten Hoopen, L. W., Knol, D. L., de Klerk, J. B., de Coo, I. F., Huijmans, J. G. M., Jakobs, C., van der Knaap, M. S., Salomons, G. S., & Mancini, G. M. S.
Affiliations
  • Department of Clinical Genetics VU University Medical Center PO Box 7057 Amsterdam 1007 MB The Netherlands
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Erasmus MC (NL)
  • Department of Child and Adolescent Psychiatry Erasmus University Medical Center Rotterdam The Netherlands
  • Department of Pediatrics, Metabolic Diseases Section Erasmus University Medical Center Rotterdam The Netherlands
  • Department of Child Neurology Erasmus University Medical Center Rotterdam The Netherlands
  • Department of Child Neurology VU University Medical Center Amsterdam The Netherlands
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2011-05-10
Volume
35
Issue
1
Pages
141-149
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2100868033
Cited by
59
References
44
Citations by year
2026: 4 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 8 · 2013: 6 · 2012: 6
FWCI
4.01
Type
journal article
Language
en
Open access
Locations
  • Journal of Inherited Metabolic Disease (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • VU Research Portal (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • ZonMw
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (917.56.349)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
X-linked intellectual disability, creatine monohydrate, L-arginine, glycine, combination therapy, 1H magnetic resonance spectroscopy, neuropsychological outcomes, IQ decline, age-related cognitive decline, long-term follow-up
MeSH terms
Arginine, Brain, Child, Child, Preschool, Creatine, Glycine, Humans, Infant, Intelligence Tests, Male, Neurons, Magnetic Resonance Spectroscopy, Amino Acid Transport Disorders, Inborn, Membrane Transport Proteins, Chromosomes, Human, X, Genes, X-Linked

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. https://app.cochat.ai/papers/10.1007/s10545-011-9345-1
The paper
van de Kamp, J. M., Pouwels, P. J. W., Aarsen, F. K., ten Hoopen, L. W., Knol, D. L., de Klerk, J. B., de Coo, I. F., Huijmans, J. G. M., Jakobs, C., van der Knaap, M. S., Salomons, G. S., & Mancini, G. M. S. (2012). Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-011-9345-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.